Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
This study is looking at two ways to give treatment for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in people who haven't been treated before. It compares giving Venetoclax for 7 days per cycle with Acalabrutinib, versus giving Venetoclax continuously for 28 days per cycle with Acalabrutinib. The goal is to see which approach leads to more complete remissions (when signs of cancer disappear) after 12 cycles of treatment. You could be eligible if you are 18 or older and have CLL or SLL that needs treatment and you haven't received prior treatment for it. The study plans to include 62 participants.
- Study design
- This is a randomized Phase II study with two groups (arms). Participants will be randomly assigned to receive either intermittent or continuous Venetoclax along with Acalabrutinib.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, complete remission, is measured after 12 cycles of treatment (each cycle is 28 days).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Zulfa Omer · PRINCIPAL_INVESTIGATOR · University of Cincinnati
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Complete Remission defined by the IWCLL 2018 criteriaPost 12 cycles of treatment (each cycle is 28 days)
Complete Remission (CR) as defined by the IWCLL 2018 criteria after 12 cycles of treatment with acalabrutinib in combination with intermittent or continuous venetoclax in patients with untreated CLL/SLL.